Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (665)	12/21/2001 2:15:20 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

OSIP 10-K is out........ As part of the assets purchased from Cadus Pharmaceutical Corporation in July 1999, we acquired a program under which we are developing several sub-type specific inhibitors of the adenosine receptor family. OSI-760 is an adenosine A1 receptor inhibitor in advanced pre-clinical development to treat the acute phase of an asthma attack. We also have several lead candidates targeting the adenosine A2B receptors that we are testing with a goal to treat the longer term damage associated with chronic asthma. Very sloppy not to have mentioned this...... Message 16703562 Bad, bad, bad. Overall, however, news appears to be good.